Looking for opinions concerning something my NIH trial doctor said when I asked if they would collaborate with Hopkins and test my circulating tumor cells for the AR-V7 variant (which they are looking into).
His concern with testing for the AR-V7 variant in my my cancer cells now, is that it may not represent the cancer that remains at the end of my current protocol. My words; but lets say Xtandi did not work for me because I do carry the AR-V7 variant now, but what if the chemo/XL-184 kills off all the AR-V7 cells; could the remaining cells now be sensitive to Zytiga?
Is the best time to test for these kind of cancer markers only valuable just prior to starting a new therapy?
Also, when they discuss cross resistance of these two drugs, could it really the fact that the first one tried had no success at killing off the AR-V7 cells, so when the next one is tried, it will not be successful either?
A recent video from the Hopkins doc
click here